# To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

> **NCT05814523** · PHASE3 · WITHDRAWN · sponsor: **Marinus Pharmaceuticals**

## Conditions studied

- Refractory Status Epilepticus

## Interventions

- **DRUG:** Ganaxolone
- **DRUG:** Placebo
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05814523
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-03
- **Primary completion:** 2024-08
- **Final completion:** 2024-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05814523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05814523, "To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05814523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*